Chronic Myeloid Leukemia in Blast Crisis
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia in Blast Crisis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML [Phase 2]
Phase 2 clinical trial evaluating asciminib in combination with standard-of-care as maintenance therapy after allogeneic stem cell transplan…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating a four-drug combination (cladribine, idarubicin, cytarabine, and venetoclax) for acute myeloid leukemia, h…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of olverembatinib with venetoclax and azacitidine for chronic myeloid leukemia in blas…
-
CLINICAL_TRIALS other · 2025-04-29Clinical Trial Update: MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing [NA]
Clinical trial update from the Medical College of Wisconsin describes a study using targeted antithymocyte globulin dosing to deplete alpha/…
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies [Phase 1]
Phase 1 study evaluating TG02 Citrate in patients with advanced hematologic malignancies has completed, including AML, ALL, blast crisis, MD…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA safety_alert · 2014-10-10PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommends additional measures to reduce the risk of blood vessel blockage with…